These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29500080)

  • 1. [Nephrotoxicity of antiretrovirals other than tenofovir].
    Loens C; Amet S; Isnard-Bagnis C; Deray G; Tourret J
    Nephrol Ther; 2018 Feb; 14(1):55-66. PubMed ID: 29500080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tenofovir nephrotoxicity].
    Isnard-Bagnis C; Aloy B; Deray G; Tourret J
    Nephrol Ther; 2016 Jun; 12(3):179-89. PubMed ID: 27017518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity as a complication of antiretroviral therapy.
    Valle R; Haragsim L
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):314-9. PubMed ID: 16815236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal safety of tenofovir disoproxil fumarate.
    Sax PE; Gallant JE; Klotman PE
    AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tenofovir on renal glomerular and tubular function.
    Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
    AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
    Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
    Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypokalemia in HIV patients on tenofovir.
    Cirino CM; Kan VL
    AIDS; 2006 Aug; 20(12):1671-3. PubMed ID: 16868451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV therapies and the kidney: some good, some not so good?
    Ryom L; Mocroft A; Lundgren J
    Curr HIV/AIDS Rep; 2012 Jun; 9(2):111-20. PubMed ID: 22370968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients.
    Rho M; Perazella MA
    Curr Drug Saf; 2007 May; 2(2):147-54. PubMed ID: 18690961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.
    Hamlin AN; Tillotson J; Bumpus NN
    Pharmacogenomics; 2019 Jan; 20(2):105-111. PubMed ID: 30628547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
    Walker UA; Bäuerle J; Laguno M; Murillas J; Mauss S; Schmutz G; Setzer B; Miquel R; Gatell JM; Mallolas J
    Hepatology; 2004 Feb; 39(2):311-7. PubMed ID: 14767983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.
    Mouton JP; Cohen K; Maartens G
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1493-1503. PubMed ID: 27498720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactic acidosis and antiretroviral therapy: a case report and literature review.
    Marra A; Lewi D; Lanzoni V; Wey SB; Odashiro LN; Gomes PS; Silva E
    Braz J Infect Dis; 2000 Jun; 4(3):151-5. PubMed ID: 10934499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal toxicity associated with tenofovir use.
    Rodriguez-Nóvoa S; Alvarez E; Labarga P; Soriano V
    Expert Opin Drug Saf; 2010 Jul; 9(4):545-59. PubMed ID: 20384533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of tenofovir induced nephrotoxicity: case reports of two patients.
    Some F; Koech M; Chesire E; Kigen G
    Pan Afr Med J; 2017; 27():126. PubMed ID: 28904656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.